Identification of TNBC subtypes is a major milestone in breast cancer with implications in the development of novel TNBC targeted therapeutics and diagnostics.
Insight Genetics licensed the technology for TNBC subtyping from Vanderbilt University and has built upon it for the development of Insight TNBCtype™.
- Transitioning the assay from fresh frozen samples to paraffin blocks
- Reducing the gene set from 2,000 to roughly 100
- Transitioning the assay from a multi-patient clustering algorithm to a single-patient assay
- Optimizing the assay for use with Next Generation Sequencing platforms
Insight TNBCtype has been validated in our CLIA and CAP accredited Insight Molecular Labs.